

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2000, 14:04:07 ; Search time 16.31 Seconds
(without alignments)
329.149 Million cell updates/sec

Title: US-09-373-230-2

Sequence: 1 NFGRLHCTTAVIRININDQVL.....KKDENGKSVFTLTINLHQS 157

Scoring table: Gapop 10.0 , Gapext 0.5

Searched: 268485 seqs, 34193795 residues

Total number of hits satisfying chosen parameters: 268485

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

A_Geneseq_36:*

- 1: /SIDSI/gcgdata/geneseq/geneseqp/AA1980.DAT:*
- 2: /SIDSI/gcgdata/geneseq/geneseqp/AA1981.DAT:*
- 3: /SIDSI/gcgdata/geneseq/geneseqp/AA1982.DAT:*
- 4: /SIDSI/gcgdata/geneseq/geneseqp/AA1983.DAT:*
- 5: /SIDSI/gcgdata/geneseq/geneseqp/AA1984.DAT:*
- 6: /SIDSI/gcgdata/geneseq/geneseqp/AA1985.DAT:*
- 7: /SIDSI/gcgdata/geneseq/geneseqp/AA1986.DAT:*
- 8: /SIDSI/gcgdata/geneseq/geneseqp/AA1987.DAT:*
- 9: /SIDSI/gcgdata/geneseq/geneseqp/AA1988.DAT:*
- 10: /SIDSI/gcgdata/geneseq/geneseqp/AA1989.DAT:*
- 11: /SIDSI/gcgdata/geneseq/geneseqp/AA1990.DAT:*
- 12: /SIDSI/gcgdata/geneseq/geneseqp/AA1991.DAT:*
- 13: /SIDSI/gcgdata/geneseq/geneseqp/AA1992.DAT:*
- 14: /SIDSI/gcgdata/geneseq/geneseqp/AA1993.DAT:*
- 15: /SIDSI/gcgdata/geneseq/geneseqp/AA1994.DAT:*
- 16: /SIDSI/gcgdata/geneseq/geneseqp/AA1995.DAT:*
- 17: /SIDSI/gcgdata/geneseq/geneseqp/AA1996.DAT:*
- 18: /SIDSI/gcgdata/geneseq/geneseqp/AA1997.DAT:*
- 19: /SIDSI/gcgdata/geneseq/geneseqp/AA1998.DAT:*
- 20: /SIDSI/gcgdata/geneseq/geneseqp/AA1999.DAT:*
- 21: /SIDSI/gcgdata/geneseq/geneseqp/AA2000.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	806	99.8	157	17 R99559	Mouse mature inter
2	806	99.8	157	17 R92506	Interferon gamma p
3	806	99.8	157	18 W15704	Mouse interferon g
4	806	99.8	157	18 W24262	Mouse protein for
5	806	99.8	157	19 W77078	Mouse Interleukin
6	806	99.8	157	19 W77159	Mouse Interleukin
7	806	99.8	157	19 W63811	Mouse IL-18 protel
8	806	99.8	157	20 Y39800	Interleukin-18 rec
9	806	99.8	157	21 Y44598	Mouse monomeric in
10	806	99.8	157	21 Y53905	Amino acid sequenc
11	806	99.8	157	21 Y57571	Murine Interleukin
12	806	99.8	180	19 W48960	Wild-type mouse in

13	797	98.6	157	19 W77090	Mouse interleukin
14	797	98.6	157	19 W48968	Mutant mouse inter
15	796	98.5	157	19 W77091	Mouse interleukin
16	796	98.5	157	19 W48969	Mutant mouse inter
17	736.5	91.2	194	19 W53282	Amino acid sequenc
18	625	77.4	175	19 W33283	Equine interleukin
19	538	66.6	193	21 Y58241	Human interleukin
20	524	64.9	157	19 W77084	Human interleukin
21	524	64.9	157	19 W48962	Mutant human inter
22	521	64.5	157	19 W77083	Human interleukin
23	521	64.5	157	19 W48961	Mutant human inter
24	518	64.1	157	19 W77077	Human interleukin
25	518	64.1	157	21 Y57570	Human interleukin
26	518	64.1	158	21 Y57570	Human interleukin
27	518	64.1	180	19 W48959	Wild-type human in
28	518	64.1	193	18 W22047	Interferon gamma i
29	518	64.1	193	19 W46592	Amino acid sequenc
30	515	63.7	157	19 W77080	Human interleukin
31	515	63.7	157	19 W77088	Human interleukin
32	515	63.7	157	19 W48966	Mutant human inter
33	515	63.7	193	19 W77082	Interleukin 18 act
34	514	63.6	157	19 W77086	Human interleukin
35	514	63.6	157	19 W48964	Mutant human inter
36	513	63.5	157	17 R99564	Human interleukin-g
37	513	63.5	157	17 R99558	Human mature inter
38	513	63.5	157	18 W15701	Interferon-gamma i
39	513	63.5	157	18 W24258	Human protein for
40	513	63.5	157	19 W77158	Human interleukin-
41	513	63.5	157	19 W63810	Human IL-18 protel
42	513	63.5	157	19 W37741	IFN-gamma inducing
43	513	63.5	157	19 W52176	Interleukin gamma I
44	513	63.5	157	20 Y39799	Interleukin-18 rec
45	513	63.5	157	21 Y44597	Human interleukin-

ALIGNMENTS

RESULT	1	
R99559		standard; Protein; 157 AA.
XX		
AC	R99559;	
XX		
DT	29-SEP-1996 (first entry)	
XX		
DE	Mouse mature interferon-gamma inducer protein.	
XX		
KW	Interferon gamma inducer protein; IFN-gamma; antiviral; virucide;	
KW	antitumor; antibacterial; immunoregulator; adoptive immunotherapy;	
KW	therapy; cancer.	
XX		
OS	Mus sp.	
XX		
FM	Key	Location/Qualifiers
FM	Misc-difference	70
FM		/Label= ile, Thr
XX		
PN	EP12931-A2.	
XX		
PD	22-MAY-1996.	
XX		
PT	10-NOV-1995.	95EP-0308055.
XX		
PR	29-SEP-1995.	95JP-0274988.
PR	15-NOV-1994.	94JP-0304203.
PR	23-FEB-1995.	95JP-0058240.
PR	10-MAR-1995.	95JP-0078357.
PR	18-SEP-1995.	95JP-0262062.
XX		
PA	(HAYB) HAYASHIBARA SEIBUTSU KAKAKU.	
XX		
PI	Fukuda S, Kohno K, Kunikata T, Kurimoto M, Okamura H;	

PI Taniguchi M, Tanimoto T, Torioge K, Ushio S;
 XX
 DR WPI: 1996-252837/26.
 DR N-PSDB: T32403.

XX DNA encoding interferon-gamma prodn. -inducing polypeptide - useful
 PT to treat and prevent, e.g. viral disease, malignancies and immune
 PT disorders

XX Example A-3-2; Page 36-37; 48pp; English.

XX A novel mouse protein (R99559) induces interferon-gamma (IFN-gamma)
 CC prodn. by immunocompetent cells. Its sequence was deduced from
 CC that of a cDNA clone (T32403) isolated from a mouse liver library.
 CC Recombinant IFN-gamma inducer protein can be produced in high yields
 CC using host cells, esp. Escherichia coli, transformed with a vector
 CC carrying the cDNA.

XX Sequence 157 AA;

Query Match 99.8%; Score 806; DB 17; Length 157;
 Best Local Similarity 100.0%; Pred. No. 6.2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NFGRLHCTTAVIRNINDQVLFVDRQPVFEDMTDIDQASASEPQRLTIYKXDESVRGLA 60
 DB 1 nfgrlhcttavrindqvlfvdrkpvfedmtddidqasasepqrlllymkdsevrqla 60

QY 61 VTLISVKSXSTLSCKNKIISFEEMDPENIDIDQSDLIFFOKRVPCHNKEFESSLYEG 120
 DB 61 vtlisvksxsstlscknkisfeemdpenniddidqsdliiffqkrvpgnhkmetesslyeg 120

QY 121 HFLACQKEDDAFKLILKKKENGDKSVMTLTNLHQS 157
 DB 121 hflacqkeddafklllkkkengdksvmtltnlhqs 157

RESULT 2

ID R92506 standard; Protein; 157 AA.

AC R92506;
 XX
 DT 02-SEP-1996 (first entry)
 XX

DE Interferon gamma production inducer protein.

KX Interferon gamma; inducer; IFNgamma; immunocompetent cell; antiviral;
 KW antitumour; antiseptic; immunoregulatory; platelet-increasing agent;
 KW therapy; prevention; condyloma acuminatum; renal cancer; brain cancer;
 KW granuloma; mycosis fungoides; rheumatism; allergy; cytotoxicity; AIDS;
 KW killer T-cell; interleukin-2; IL-2; tumour necrosis factor; TNF;
 KW adoptive immunotherapy; monoclonal antibody.

XX Mus musculus.

XX Key Location/Qualifiers
 FH Misc-difference 70
 FT /Label= Met, Thr

XX EP692536-A2.

XX 17-JAN-1996.

XX 13-JUL-1995; 95EP-0304906.

XX 10-FEB-1995; 95JP-0045057.

XX 14-JUL-1994; 94JP-0184162.

XX (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.

XX Kohno K, Kunikata T, Kurimoto M, Okamura H, Taniguchi M;
 PI

PI Tanimoto T, Torioge K;
 XX
 DR WPI: 1996-070177/08.
 DR N-PSDB: T92506.

XX Protein that induces gamma interferon prodn. in immuno-competent
 PT cells - used e.g. as antiviral or antitumour agent, also induces
 PT cytotoxicity of killer cells

XX Claim 2; Page 22; 30pp; English.

XX This sequence represents the interferon gamma (IFNgamma) inducer protein
 CC of the invention. This protein induces IFNgamma production in
 CC immunocompetent cells. The protein is useful as an antiviral,
 CC antitumour, antiseptic, immunoregulatory and platelet-increasing agent.
 CC It can be used for treating or preventing AIDS, condyloma acuminatum,
 CC renal or brain cancer, granuloma, mycosis fungoides, rheumatism and
 CC allergy. The protein can also be used to induce IFNgamma production in
 CC cultured cells. The IFNgamma inducer strongly induces cytotoxicity of
 CC killer T-cells and when used with interleukin-2 (IL-2) and tumour
 CC necrosis factor (TNF), may improve the effect (or reduce side effects) of
 CC adoptive immunotherapy in tumours. The DNA encoding this sequence can
 CC be used to produce the protein, which can then be purified (or assayed)
 CC using monoclonal antibodies.

XX Sequence 157 AA;

Query Match 99.8%; Score 806; DB 17; Length 157;
 Best Local Similarity 100.0%; Pred. No. 6.2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NFGRLHCTTAVIRNINDQVLFVDRQPVFEDMTDIDQASASEPQRLTIYKXDESVRGLA 60
 DB 1 nfgrlhcttavrindqvlfvdrkpvfedmtddidqasasepqrlllymkdsevrqla 60

QY 61 VTLISVKSXSTLSCKNKIISFEEMDPENIDIDQSDLIFFOKRVPCHNKEFESSLYEG 120
 DB 61 vtlisvksxsstlscknkisfeemdpenniddidqsdliiffqkrvpgnhkmetesslyeg 120

QY 121 HFLACQKEDDAFKLILKKKENGDKSVMTLTNLHQS 157
 DB 121 hflacqkeddafklllkkkengdksvmtltnlhqs 157

RESULT 3

ID W15704 standard; peptide; 157 AA.

AC W15704;

DT 26-JAN-1998 (first entry)

DE Mouse interferon-gamma inducer protein.

KX Interferon-gamma, IFN-gamma; antiviral; antineoplastic; radiotherapy;
 KW immunoregulatory; antitumour agent; chemotherapy; leukopenia;
 KW thrombocytopenia; immunocompetent cell; asthma; hayfever;
 KW rheumatism; interleukin; killer cell.

XX Mus musculus.

XX Key Location/Qualifiers
 FH Misc-difference 70
 FT /Label= Met, Thr

XX EP767178-A1.

XX 09-APR-1997.

XX 26-SEP-1996; 96EP-0306997.

XX 20-SEP-1996; 96JP-0269105.

PR 26-SEP-1995; 95JP-0270725.
 PR 29-FEB-1996; 96JP-0067434.
 XX
 XX (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI Akita K, Fujii M, Kurimoto M, Nakada Y, Tanimoto T;
 XX WPI; 1997-205381/19.
 DR N-PSDB; T60536.
 XX
 PT Human protein that induces interferon-gamma produ. in
 PT immuno:competent cells - useful for adoptive immuno:therapy of
 PT tumours and as antimicrobial agent etc.
 XX
 PS Disclosure; Page 22; 26pp; English.
 XX
 CC The present sequence represents a novel protein from mouse liver cells,
 CC which induces interferon-gamma (IFN gamma) production in immunocompetent
 CC cells. This protein enhances cytotoxicity of killer cells and induces
 CC their formation. It is used as an antitumor agent for antitumor
 CC immunotherapy, an antiviral (including anti-AIDS) or antibacterial agent,
 CC and in the treatment of atopic or immune system diseases, e.g. asthma,
 CC hay fever or rheumatism. When formulated with interleukin-3, it is also
 CC used to treat leukopenia and thrombocytopenia associated with
 CC radiotherapy or chemotherapy of leukemia and other cancers. When used
 CC in antitumor immunotherapy, this novel protein significantly improves
 CC the immunotherapeutic effect of interleukin-2 (IL-2), compared with use
 CC of IL-2 alone, either when administered to the patient (before
 CC administration of IL-2) or by addition to the medium in which cells
 CC (intended for return to the patient) are being grown.
 XX
 SQ Sequence 157 AA;
 XX
 Query Match 99.8%; Score 806; DB 18; Length 157;
 Best Local Similarity 100.0%; Pred. No. 6, 2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 NFGRLHCTAVIRNINDQVLFVDKROPVEDMTDIDQASBPQRLIYKYDSEVRLA 60
 DB 1 nfgrlhctavirndqvlfvdkrpvedmtidqasbpqrlliykydsevrqla 60
 QY 61 VTLVSDKXSTLSCNKKIISFEMDPENIDIDSLIFQKRVPGHNKMEFESSLYEG 120
 DB 61 vtlsvdkxstlscnkkisfeemdpennididslifqkrvpghnkmeffesslyeg 120
 QY 121 HFLACQKEDDAFKLILKKKDKNGDKSVMTLTNLHQS 157
 DB 121 hflacqkeddafkllilkkkdkngdksvmtltlnlqs 157
 XX
 RESULT 4
 W24262 ID W24262 standard; Protein; 157 AA.
 XX
 AC W24262;
 XX
 DT 15-OCT-1997 (first entry)
 XX
 DE Murine protein for induction of interferon-gamma.
 XX
 KW Interferon-gamma; immunocompetent cell; malignant tumour;
 KW viral disease; bacterial infection; immune disease.
 XX
 OS Mus musculus.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 70
 XX (note= "Encoded by AYT"
 XX JP09157180-A.
 XX
 PD 17-JUN-1997.

XX
 PF 24-JAN-1996; 96JP-0028722.
 XX
 PR 04-OCT-1995; 95JP-0279906.
 PR 10-MAR-1995; 95JP-0078357.
 PR 29-SEP-1995; 95JP-0274988.
 XX
 XX (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI WPI; 1997-369391/34.
 DR N-PSDB; T80210.
 XX
 PT A drug containing a polypeptide which induces interferon-gamma -
 PT useful for treating e.g. malignant tumours, viral, bacterial or
 PT immune diseases
 XX
 PS Disclosure; Page 10-11; 12pp; Japanese.
 XX
 CC This sequence represents a protein which induces interferon-gamma
 CC production in immunocompetent cells. This protein may be used as
 CC the major component in a drug for the prevention and treatment of
 CC e.g. malignant tumours, viral diseases, bacterial infections and
 CC immune diseases.
 XX
 SQ Sequence 157 AA;
 XX
 Query Match 99.8%; Score 806; DB 18; Length 157;
 Best Local Similarity 100.0%; Pred. No. 6, 2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 NFGRLHCTAVIRNINDQVLFVDKROPVEDMTDIDQASBPQRLIYKYDSEVRLA 60
 DB 1 nfgrlhctavirndqvlfvdkrpvedmtidqasbpqrlliykydsevrqla 60
 QY 61 VTLVSDKXSTLSCNKKIISFEMDPENIDIDSLIFQKRVPGHNKMEFESSLYEG 120
 DB 61 vtlsvdkxstlscnkkisfeemdpennididslifqkrvpghnkmeffesslyeg 120
 QY 121 HFLACQKEDDAFKLILKKKDKNGDKSVMTLTNLHQS 157
 DB 121 hflacqkeddafkllilkkkdkngdksvmtltlnlqs 157
 XX
 RESULT 5
 W77078 ID W77078 standard; Protein; 157 AA.
 XX
 AC W77078;
 XX
 DT 14-DEC-1998 (first entry)
 XX
 DE Mouse interleukin 18 protein.
 XX
 KW Mouse; interleukin-18; IL-18; osteoclast; hypercalcaemia; osteopenia;
 KW osteoclastoma Benquet's syndrome; osteosarcoma; arthropathy; osteoporosis;
 KW chronic rheumatoid arthritis; deformity ositits; primary hyperthyroidism.
 XX
 OS Mus sp.
 XX
 FH EP861663-A2.
 FT 02-SEP-1998.
 XX
 PF 24-FEB-1998; 98EP-0301352.
 XX
 PR 25-FEB-1997; 97JP-0055468.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI Gillespie MT, Horwood NJ, Kurimoto M, Udagawa N;
 XX WPI; 1998-448964/39.

DR N-PSDB; V48227.

XX Use of interleukin-18 to inhibit osteoclast formation - in treatment
PT of e.g. hypercalcaemia, osteoclastoma, Behcet's syndrome,
PS osteosarcoma, chronic rheumatoid arthritis, deformity osteitis,
XX primary hyperthyroidism and osteoporosis

XX Claim 6; Page 19; 56pp; English.

CC Interleukin-18 (IL-18) or a functional equivalent can be used for
CC inhibition of osteoclast formation. IL-18 is used for treating or
CC preventing osteoclast-related diseases e.g. hypercalcaemia, osteoclastoma
CC Behcet's syndrome, osteosarcoma, arthropathy, chronic rheumatoid
CC arthritis, deformity osteitis, primary hyperthyroidism, osteopenia and
CC osteoporosis.

XX Sequence 157 AA;

Query Match 99.8%; Score 806; DB 19; Length 157;
Best Local Similarity 99.4%; Pred. No. 6.2e-79;
Matches 156; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 NFGRLHCTTAVIRININDQVLFVKKRPVEFDMTDIDQSASEPQRLIITMYKDESEVRLA 60
DB 1 nfgrlhcttavrindqvlfvdkrqvfdemtdidqsasepqrlllymykdeevrgla 60
OY 61 VTLAVKDSKXSTLSCKNKIISFEEMDPENIDIDQSDFFOKRVPGHKKMEFESSLYEG 120
DB 61 vtlavkdsksstlscknkisfeemdpennididqsdllffqkrvpgnhkmeffesslyeg 120
OY 121 HFLACQKEDDAFKLILKKKDENGDKSVMTLTNLHQS 157
DB 121 hflacqkeddafklllkkkdeengdksvmftltnlhqs 157

RESULT 6
W77159 standard; protein; 157 AA.

XX W77159;
DT 26-NOV-1998 (first entry)
XX
DE Murine interleukin-18 protein (IL-18).
XX
KW Murine; interleukin-18 receptor; IL-18R; cytokine; signal transduction;
KW immune system; treatment; autoimmunity; allergic disease;
KW immunosuppressant.

XX Mus sp.

XX Location/Qualifiers
FH Key 70
FT Misc-difference /note= "Met or Thr"

XX EP864585-A1.

XX 16-SEP-1998.

XX 23-DEC-1997; 97EP-0310517.

XX 09-OCT-1997; 97JP-0291837.

XX 12-MAR-1997; 97JP-0074697.

XX 28-JUL-1997; 97JP-0215488.

XX (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.

XX Kurimoto M, Okura T, Torioge K;

XX WPI; 1998-469188/41.

XX Interleukin-18 receptor polypeptide(s) - and corresponding DNA,

PT which peptide compounds are useful for treating auto-immune or
XX allergic diseases

PS Disclosure; Page 42; 51pp; English.

XX The present sequence represents a murine interleukin-18 (IL-18)
CC polypeptide. Interleukin-18 is a type of cytokine which mediates signal
CC transduction in immune systems. The interleukin-18 receptor polypeptide
CC can be used to neutralise interleukin-18 activity or to treat
CC autoimmune or allergic diseases or as an immunosuppressant. Conditions
CC which may be treated include e.g. graft or organ rejection, pernicious
CC anaemia, insulin-related diabetes, discoid lupus erythematosus,
CC ulcerative colitis, hyperthyroidism, auto-immune hepatitis, systemic
CC scleroderma, polymyositis, leukopenia, rheumatoid arthritis, HIV
CC infections, asthma, atopic dermatitis, and pollinosis. The products may
CC also be useful in the treatment of septic shock associated with
CC IFN-alpha.

XX Sequence 157 AA;

Query Match 99.8%; Score 806; DB 19; Length 157;
Best Local Similarity 100.0%; Pred. No. 6.2e-79;
Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NFGRLHCTTAVIRININDQVLFVKKRPVEFDMTDIDQSASEPQRLIITMYKDESEVRLA 60
DB 1 nfgrlhcttavrindqvlfvdkrqvfdemtdidqsasepqrlllymykdeevrgla 60
OY 61 VTLAVKDSKXSTLSCKNKIISFEEMDPENIDIDQSDFFOKRVPGHKKMEFESSLYEG 120
DB 61 vtlavkdsksstlscknkisfeemdpennididqsdllffqkrvpgnhkmeffesslyeg 120
OY 121 HFLACQKEDDAFKLILKKKDENGDKSVMTLTNLHQS 157
DB 121 hflacqkeddafklllkkkdeengdksvmftltnlhqs 157

RESULT 7
W63811 standard; protein; 157 AA.

XX W63811;
DT 28-SEP-1998 (first entry)
XX
DE Mouse IL-18 protein fragment.

XX

KW Interleukin-18; IL-18; murine; treatment; autoimmunity; antibody;
KW immunosuppressant; inhibitor; receptor protein; detection.

XX Mus sp.

XX Location/Qualifiers
FH Key 1.157
FT Protein /label= IL-18

FT Misc-difference /note= "partial sequence"

FT /label= Met or Thr

XX EP850952-A1.

XX 01-JUL-1998.

XX 23-DEC-1997; 97EP-0310555.

XX 28-JUL-1997; 97JP-0215490.

XX 26-DEC-1996; 96JP-0356426.

XX 21-FEB-1997; 97JP-0052526.

XX 06-JUN-1997; 97JP-0163490.

XX (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.

XX KIunkata T, Kurimoto M, Torigoe K, Ushio S;
 XX WPI: 1998-335317/30.
 DR
 XX
 PT New interleukin-18 receptor protein used to inhibit interleukin-18,
 PT to treat autoimmune disease and as immunosuppressant - and new
 PT monoclonal antibody and hybridoma used to detect interleukin -18
 PT receptor protein
 PS
 PS Claim 5; Page 16-17; 35pp; English.
 CC This sequence represents a mouse interleukin-18 (IL-18) fragment which is
 CC used in a method involved in neutralising IL-18 or to treat autoimmune
 CC diseases or as an immunosuppressant using anti-IL-18 antibodies which
 CC can inhibit IL-18. Such antibodies can also be used to detect the IL-18
 CC receptor protein (labelled with an enzyme or a radioactive or fluorescent
 CC substance). The protein is used to treat e.g. graft rejection, pernicious
 CC anaemia, atrophic gastritis, insulin-resistant diabetes, Megener
 CC granulomatosis, discoid lupus erythematosus, ulcerative colitis,
 CC biliary cirrhosis, sympathetic ophthalmitis, hyperthyroidism, juvenile
 CC onset type diabetes, Sjogren syndrome, autoimmune hepatitis, systemic
 CC haemolytic anaemia, myasthenia gravis, systemic sclerosis, systemic
 CC periarthritis nodosa, multiple sclerosis, Addison's disease, purpura
 CC haemorrhagica, Basedow's disease, leukopaenia, Behcet's disease,
 CC climacterium praecox, rheumatoid arthritis, rheumatopyra, chronic
 CC thyroiditis, Hodgkin's disease, HIV, asthma, atopic dermatitis, allergic
 CC naitis, pollinosis, aptoxin-allergy and septic shock resulting from
 CC production or administration of excessive gamma interferon (IFN-gamma).
 CC
 SO Sequence 157 AA:
 99.8%; Score 806; DB 19; Length 157;
 Query Match Best Local Similarity 100.0%; Pred. No. 6,2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 NFGRLCTTAVIRINDOYLFDKRPVFEEDMTDIDQASBPOTRLIYYMKSEYRGIA 60
 DB 1 nfgrlhcttavrindvlyfdkrpvyfedmdtdqasbpotrlillymksevyrgia 60
 QY 61 VTLGVKDSKXSTLSCNKKIISFEEMDPENIDIOSDLFFOKRYPGHNKMEFESSLYEG 120
 DB 61 vtlsvkdsksxstlscknkliisfeemdpennidiosdlffokrypgnkmefesslyeg 120
 QY 121 HFLACOKEDDAFLIKKKDKDNGKSVFRTLNLHQS 157
 DB 121 hflacokeddafllkkkdkdngksvmtltnlhrs 157
 RESULT 8
 ID Y39800 standard; Protein: 157 AA.
 AC Y39800;
 XX
 DT 29-NOV-1999 (first entry)
 DE Interleukin-18 receptor protein sequence fragment.
 XX
 KW Interleukin-18 receptor; IL-18; human; mouse; organ transplant rejection;
 KW IL-18 receptor sensitive disease; immune reaction; therapy.
 XX
 OS Mammalia.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 70 /note= "unspecified amino acid"
 XX
 PN JPI1240898-A.

PD 07-SEP-1999.
 XX
 PF 12-MAR-1998; 98JP-0078549.
 XX
 PR 12-MAR-1997; 97JP-0074697.
 PR 28-JUN-1997; 97JP-0215488.
 PR 09-OCT-1997; 97JP-0291837.
 PR 26-DEC-1997; 97JP-0366908.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAKAKU.
 XX
 DR WPI: 1999-555071/47.
 XX
 PT New polypeptide - useful against interleukin-18 receptor sensitive
 PT diseases
 PS
 PS Disclosure; Page 37-38; 41pp; Japanese.
 CC This sequence is a fragment of an interleukin-18 receptor (IL-18R) of the
 CC invention. The IL-18R sequences were isolated from human and mouse. The
 CC sequences can be used in drugs for treating IL-18 receptor sensitive
 CC disease, especially effective for the relief of rejection accompanied to
 CC organ transplantation and for the treatment and the prevention of various
 CC diseases caused by excessive immune reaction.
 CC
 SO Sequence 157 AA:
 99.8%; Score 806; DB 20; Length 157;
 Query Match Best Local Similarity 100.0%; Pred. No. 6,2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 NFGRLCTTAVIRINDOYLFDKRPVFEEDMTDIDQASBPOTRLIYYMKSEYRGIA 60
 DB 1 nfgrlhcttavrindvlyfdkrpvyfedmdtdqasbpotrlillymksevyrgia 60
 QY 61 VTLGVKDSKXSTLSCNKKIISFEEMDPENIDIOSDLFFOKRYPGHNKMEFESSLYEG 120
 DB 61 vtlsvkdsksxstlscknkliisfeemdpennidiosdlffokrypgnkmefesslyeg 120
 QY 121 HFLACOKEDDAFLIKKKDKDNGKSVFRTLNLHQS 157
 DB 121 hflacokeddafllkkkdkdngksvmtltnlhrs 157
 RESULT 9
 ID Y44598 standard; Protein: 157 AA.
 AC Y44598;
 XX
 DT 04-APR-2000 (first entry)
 DE Mouse monoclonic interleukin-18.
 XX
 KW Mouse interleukin-18; IL-18; anti-IL-18-antibody; immunopathies;
 KW inflammatory disorder; autoimmune disease; anti-allergic;
 KW anti-inflammatory; immunosuppressive; hematopoietic; leukocytopoietic;
 KW antiaplgic; antipyretic.
 XX
 OS Mus musculus.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 70 /label= Met, Thr
 XX
 PN EP974600-A2.
 XX
 PD 26-JAN-2000.
 XX
 PF 24-JUN-1999; 99EP-0304977.
 XX
 PR 24-JUN-1998; 98JP-0177580.

PR 12-OCT-1998; 98JP-0289044.
 PR 22-DEC-1998; 98JP-0365023.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI Nishida Y, Okura T, Tanimoto T, Kurimoto M;
 XX WPI: 2000-118341/11.
 DR
 XX New artificially produced peptide for neutralizing biological activity
 PT of interleukin-18, useful for treating and preventing immunopathies,
 PR inflammatory disorders and autoimmune diseases -
 XX
 PS Disclosure; Page 27; 32pp; English.
 CC
 CC The present sequence is mouse monomeric interleukin-18. This can comprise
 CC a part or the whole of the variable region in anti-interleukin-18
 CC -antibody for neutralising interleukin-18. This is useful for treating
 CC and preventing immunopathies, inflammatory disorders and autoimmune
 CC diseases which are caused by excessive immunoreaction. The protein has
 CC anti-allergic, anti-inflammatory, immunosuppressive, hematopoietic,
 CC leukocytopenic, antialgic, antipyretic and hepatic-function improving
 CC activities.
 CC
 XX Sequence 157 AA;
 SQ

Query Match 99.8%; Score 806; DB 21; Length 157;
 Best Local Similarity 100.0%; Pred. No. 6.2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NFGRLHCTTAVIRININDQVLFVDRKQPVFEDMTIDQSASEPQRLTIYMKSEVGLA 60
 Db 1 nfgrlhcttavirindqvlfdkrqpvfedmtidqsasepqrlliyymksevgla 60
 QY 61 VTLVSKDSKXSTLSCKNNIISFEEMDPENIDDIQSDLIFFQKRVPGHNKMEFESSLYEG 120
 Db 61 vtlsvkdsksxlscnknlisfeemdpenniddiqsdliiffqkrvpghnkmeffesslyeg 120
 QY 121 HFLACOKEDDAFKLILKKKDKNGSKSVFRTLNLHOS 157
 Db 121 hflacokeddafklllkkkdkngsksvmftltnlhrs 157

RESULT 10
 ID Y53905 standard; Protein: 157 AA.
 XX
 AC Y53905;

DT 13-MAR-2000 (first entry)

XX Amino acid sequence of a protein that induces IFN-gamma production.

KW Mouse; interferon gamma production; IFN-gamma; immunocompetent cell;
 KW antiviral; immunoregulatory; antigen; mitogen;
 KW IFN-gamma susceptible disease; antibacterial; antitumor;
 KW blood platelet enhancing agent; hepatitis; herpes syndrome; condyloma;
 KW AIDS; bacterial disease; candidiasis; malaria; solid malignant tumour;
 KW renal cancer; mycosis fungoides; chronic granulomatous disease;
 KW blood cell malignant tumour; adult T cell leukaemia;
 KW chronic myelogenous leukaemia; malignant leukaemia; immune disease;
 KW allergy; rheumatism.
 XX
 OS Mus sp.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 70 /note="unspecified residue encoded by AVG"
 XX
 XX EP962531-A2.
 XX
 XX 08-DEC-1999.

XX
 PF 10-NOV-1995; 99EP-0104104.
 XX
 XX 15-NOV-1994; 94JP-0304203.
 PR 23-FEB-1995; 95JP-0058240.
 PR 10-MAR-1995; 95JP-0078357.
 PR 18-SEP-1995; 95JP-0262062.
 PR 29-SEP-1995; 95JP-0274988.
 PR 10-NOV-1995; 95EP-0308055.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI Ushio S, Torigoe K, Tanimoto T, Okamura H;
 DR WPI: 2000-064289/06.
 DR N-PSDB; Z36923.
 XX
 PT Novel polypeptides used in the treatment of interferon-gamma
 PT susceptible diseases -
 XX
 PS Disclosure; Page 3; 42pp; English.
 CC
 CC The present sequence represents a murine protein that induces interferon
 CC (IFN)-gamma production by immunocompetent cells. IFN-gamma is a
 CC protein which has antiviral, antineoplastic and immunoregulatory activities,
 CC and is produced by immunocompetent cells stimulated with antigens or
 CC mitogens. A probe derived from the cDNA of the present sequence was used
 CC to isolate the corresponding human protein from human liver cells. The
 CC protein of the invention is used to treat IFN-gamma susceptible diseases,
 CC and also have use as a antiviral agent, antibacterial agent, antitumor
 CC agent, immunoregulatory agent and blood platelet enhancing agent.
 CC Diseases which can be treated with the protein include viral diseases
 CC such as hepatitis, herpes syndrome, condyloma, and AIDS; bacterial
 CC diseases such as candidiasis and malaria; solid malignant tumours such
 CC as renal cancer, mycosis fungoides, and chronic granulomatous disease;
 CC blood cell malignant tumours such as adult T cell leukaemia, chronic
 CC myelogenous leukaemia, and malignant leukaemia; and immune diseases
 CC such as allergy and rheumatism.
 CC
 XX Sequence 157 AA;
 SQ

Query Match 99.8%; Score 806; DB 21; Length 157;
 Best Local Similarity 100.0%; Pred. No. 6.2e-79;
 Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NFGRLHCTTAVIRININDQVLFVDRKQPVFEDMTIDQSASEPQRLTIYMKSEVGLA 60
 Db 1 nfgrlhcttavirindqvlfdkrqpvfedmtidqsasepqrlliyymksevgla 60
 QY 61 VTLVSKDSKXSTLSCKNNIISFEEMDPENIDDIQSDLIFFQKRVPGHNKMEFESSLYEG 120
 Db 61 vtlsvkdsksxlscnknlisfeemdpenniddiqsdliiffqkrvpghnkmeffesslyeg 120
 QY 121 HFLACOKEDDAFKLILKKKDKNGSKSVFRTLNLHOS 157
 Db 121 hflacokeddafklllkkkdkngsksvmftltnlhrs 157

RESULT 11
 ID Y57571 standard; protein: 157 AA.
 XX
 AC Y57571;

DT 06-MAR-2000 (first entry)

XX Murine interleukin 18 protein sequence SEQ ID NO:2.

KW Murine; interleukin 18; IL-18; potentiaator; IGF1; tumour; cancer;
 KW interferon-gamma-inducing factor; growth inhibition; cytostatic.
 XX
 OS Mus sp.

XX WO959565-A1.
 PN 25-NOV-1999.
 PD 20-MAY-1999; 99WO-US11160.
 XX 21-MAY-1998; 98US-0086560.
 PR (SMIK) SMITHKLINE BEECHAM CORP.
 XX Johnson RK;
 PI WPI: 2000-062368/05.
 DR New polypeptides, useful for preparation of composition for preventing
 XX and/or treating cancer by inhibiting tumor growth -
 PT Claim 2; Page 50; 53pp; English.
 PS
 CC The present sequence represents murine interleukin 18 (IL-18). The
 CC present invention describes a compound comprising human or murine IL-18
 CC in combination with a chemotherapeutic agent (1). Also described are:
 CC (1) a method of preventing and/or treating cancer in a mammal comprising
 CC the administration of a cancer inhibiting amount of (1) comprising the
 CC IL-18 protein and the chemotherapeutic agent and optionally a
 CC pharmaceutically acceptable carrier; and (2) a method of inhibiting the
 CC growth of tumor cells in a mammal sensitive to a composition comprising
 CC human IL-18 and/or murine IL-18 and the chemotherapeutic agent (and
 CC optionally a pharmaceutically acceptable carrier), comprising
 CC administering to a mammal afflicted with the tumor cells an effective
 CC tumor cell growth inhibiting amount of (1). The IL-18 protein in
 CC conjunction with a chemotherapeutic agent is useful in a method for
 CC preventing and/or treating cancer in mammals by inhibiting the growth
 CC of tumours or cancerous cells in mammals.
 XX Sequence 157 AA:
 SO
 Query Match 99.8%; Score 806; DB 21; Length 157;
 Best Local Similarity 99.4%; Pred. No. 6.2e-79;
 Matches 156; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 NFGRLCTTAVIRNINDVLFVDRKQPVFEDMTDIDQASSEPQRLIITYWKDSEVRGIA 60
 DB 1 nfgrlhcttavrlnndgvlfdvdrkqvfeadmtdidqassepqrlillymkdsevrigia 60
 OY 61 VTLSVKDSKXSTLSCKNKKIISFEEMDPENIDIOSDLIFQKRVPGHNKMEFESSLYEG 120
 DB 61 vtlsvkdsksmstlscknkkisfeemdpennididqsdllffqkrvpgnhkmetesslyeg 120
 OY 121 HFLACQKEDDAFKLILKKKDKNGSDKSYMFTLTNLHQS 157
 DB 121 hflacqkedaafklllkkkdkngsdksymftltlnlqs 157
 RESULT 12
 W48960 ID W48960 standard; Peptide; 180 AA.
 XX
 AC W48960;
 DT 25-SEP-1998 (first entry)
 XX
 DE Wild-type mouse interferon-gamma inducing factor.
 XX Interferon-gamma inducing factor; interferon-gamma; killer cell,
 KW antitumour agent; antiviral agent; antimicrobial agent; tumour; mGIF;
 KW hepatitis; malaria; tuberculosis; renal carcinoma; rheumatism; AIDS;
 XX osteoporosis; thrombopenia; acquired immunodeficiency syndrome.
 XX Mus sp.
 XX

PH Key Location/Qualifiers
 PT Peptide 1..23
 FT /note= "Signal peptide"
 FT Protein 24..180
 FT /note= "Mature mouse IGIF which is claimed by the
 FT inventors under claim 4 in the specification"
 PN EP845530-A2.
 XX 03-JUN-1998.
 PD 28-NOV-1997; 97EP-0309632.
 PF 14-NOV-1997; 97JP-0329715.
 XX 29-NOV-1996; 96JP-0333037.
 PR 21-JAN-1997; 97JP-0020906.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX Kurimoto M, Okamoto I, Yamamoto K;
 PI WPI: 1998-288747/26.
 DR N-PSDB: V32755.
 DR Mutants of interferon-gamma inducing polypeptide - useful as
 XX antitumour, antiviral, antimicrobial or anti-immunopathic agents
 PS Claim 4; pages 38-39; 59pp; English.
 CC The present sequence represents the wild-type mouse interferon-gamma
 CC inducing factor (mGIF). The invention provides for mutant human and
 CC mouse interferon-gamma inducing factors in which one or more cysteine
 CC residues are replaced with different residues at or away from the
 CC consensus sequences shown in W48956-W48958. The mutant mGIFs are
 CC capable of stimulating immunocompetent cells for the production of
 CC interferon-gamma and are claimed to be less toxic, more active and stable
 CC than the corresponding wild type mGIF. The mutant mGIFs are also
 CC claimed to enhance killer cell cytotoxicity and/or induce killer cell
 CC formation, and may therefore be useful as antitumour agents, antitumour
 CC immunotherapeutics, antiviral agents and antimicrobial agents. The
 CC mutant mGIFs are also claimed to be useful for treating hepatitis,
 CC acquired immunodeficiency syndrome (AIDS), malaria, tuberculosis, solid
 CC malignant tumours (e.g. renal carcinoma), rheumatism, osteoporosis and
 CC thrombopenia caused by radiation- and chemo-therapy.
 XX Sequence 180 AA:
 SO
 Query Match 99.8%; Score 806; DB 19; Length 180;
 Best Local Similarity 99.4%; Pred. No. 7.5e-79;
 Matches 156; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 NFGRLCTTAVIRNINDVLFVDRKQPVFEDMTDIDQASSEPQRLIITYWKDSEVRGIA 60
 DB 24 nfgrlhcttavrlnndgvlfdvdrkqvfeadmtdidqassepqrlillymkdsevrigia 83
 OY 61 VTLSVKDSKXSTLSCKNKKIISFEEMDPENIDIOSDLIFQKRVPGHNKMEFESSLYEG 120
 DB 84 vtlsvkdsksmstlscknkkisfeemdpennididqsdllffqkrvpgnhkmetesslyeg 143
 OY 121 HFLACQKEDDAFKLILKKKDKNGSDKSYMFTLTNLHQS 157
 DB 144 hflacqkedaafklllkkkdkngsdksymftltlnlqs 180
 RESULT 13
 W77090 ID W77090 standard; Peptide; 157 AA.
 XX
 AC W77090;
 DT 16-NOV-1998 (first entry)
 XX

DE Mouse interleukin 18 derivative 1.
 XX
 KW Mouse; interleukin-18; IL-18; osteoclast; hypercalcaemia; osteopenia;
 KW osteoclastoma Behcet's syndrome; osteosarcoma; arthropathy; osteoporosis;
 KW chronic rheumatoid arthritis; deformity osteitis; primary hyperthyroidism.
 XX
 OS Mus sp.
 XX
 PN EP861663-A2.
 XX
 PD 02-SEP-1998.
 XX
 PF 24-FEB-1998; 98EP-0301352.
 XX
 PR 25-FEB-1997; 97JP-0055468.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI Gillespie MT, Horwood NJ, Kurimoto M, Udagawa N;
 DR WPI; 1998-448964/39.
 XX
 XX Use of interleukin-18 to inhibit osteoclast formation - in treatment
 PT of e.g. hypercalcaemia, osteoclastoma, Behcet's syndrome,
 PT osteosarcoma, chronic rheumatoid arthritis, deformity osteitis,
 PI primary hyperthyroidism and osteoporosis
 XX
 PS Disclosure; Page 34; 56pp; English.
 XX
 CC Interleukin-18 (IL-18) or a functional equivalent can be used for
 CC inhibition of osteoclast formation. IL-18 is used for treating or
 CC preventing osteoclast-related diseases e.g. hypercalcaemia, osteoclastoma
 CC Behcet's syndrome, osteosarcoma, arthropathy, chronic rheumatoid
 CC arthritis, deformity osteitis, primary hyperthyroidism, osteopenia and
 CC osteoporosis.
 XX
 SQ Sequence 157 AA;
 Query Match 98.6%; Score 797; DB 19; Length 157;
 Best Local Similarity 98.7%; Pred. No. 5.7e-78;
 Matches 155; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 NFGRLHCTTAVIRNINDQVLFVDKRPVEFDMTDIDQASSEPQRLIIYMYKDEVRGLA 60
 Db 1 nfgrlhattavirlnndqylfvdkrqpvedmdtdqasasepqrlllymykdevrqla 60
 QY 61 VTLVSKDSKXSTLSCNKKIISFEEMDPENIDIOSDLFFQKRVYGHKKMEFESSLYEG 120
 Db 61 vtlsvkdsksmstlscnkkisfeemdpennididqsdllffqkrvpgnhkmetesslyeg 120
 QY 121 HFLACQKEDDAFKLLIKKKDENGDKSVMTLTNLHQS 157
 Db 121 hflacqkeddafklllkkkdengdksvmtltlnlbg 157
 RESULT 14
 W48968 standard; Peptide: 157 AA.
 AC W48968;
 XX
 DT 25-SEP-1998 (first entry)
 XX
 DE Mutant mouse interferon-gamma inducing factor mIGIF/MUT11.
 XX
 KW Interferon-gamma inducing factor; interferon-gamma; killer cell;
 KW antitumour agent; antiviral agent; antimicrobial agent; tumour; mIGIF;
 KW hepatitis; malaria; tuberculosis; renal carcinoma; rheumatism; AIDS;
 KW osteoporosis; thrombopenia; acquired immunodeficiency syndrome.
 XX
 OS Mus sp.
 OS Synthetic.

XX Key Location/Qualifiers
 FH Misc-difference 7
 FT /note= "changed from Cys in wild-type to Ala in
 FT mutant"
 FT
 XX
 PN EP845530-A2.
 XX
 PD 03-JUN-1998.
 XX
 PF 28-NOV-1997; 97EP-0309632.
 XX
 PR 14-NOV-1997; 97JP-0329715.
 PR 29-NOV-1996; 96JP-0333037.
 PR 21-JAN-1997; 97JP-0020906.
 XX
 PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.
 XX
 PI Kurimoto M, Okamoto I, Yamamoto K;
 DR WPI; 1998-288747/26.
 DR N-PSDB; V32632.
 XX
 XX Mutants of interferon-gamma inducing polypeptide - useful as
 PT antitumour, antiviral, antimicrobial or anti-immunopathic agents
 XX
 PS Claim 6; page 44; 59pp; English.
 XX
 CC The present sequence represents the mutant mouse interferon-gamma
 CC inducing factor mIGIF/MUT11. The wild-type mouse interferon-gamma
 CC factor (mIGIF) sequence is shown in W48960. The invention provides for
 CC mutant human and mouse interferon-gamma inducing factors in which one
 CC or more cysteine residues are replaced with different residues at or away
 CC from the consensus sequences shown in W48956-W48958. The mutant mIGIFs
 CC are capable of stimulating immunocompetent cells for the production of
 CC interferon-gamma and are claimed to be less toxic, more active and stable
 CC than the corresponding wild type mIGIF. The mutant mIGIFs are also
 CC claimed to enhance killer cell cytotoxicity and/or induce killer cell
 CC formation, and may therefore be useful as antitumour agents, antitumour
 CC immunotherapeutics, antiviral agents and antimicrobial agents. The
 CC mutant mIGIFs are also claimed to be useful for treating hepatitis,
 CC acquired immunodeficiency syndrome (AIDS), malaria, tuberculosis, solid
 CC malignant tumours (e.g. renal carcinoma), rheumatism, osteoporosis and
 CC thrombopenia caused by radiation- and chemo-therapy.
 XX
 SQ Sequence 157 AA;
 Query Match 98.6%; Score 797; DB 19; Length 157;
 Best Local Similarity 98.7%; Pred. No. 5.7e-78;
 Matches 155; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 NFGRLHCTTAVIRNINDQVLFVDKRPVEFDMTDIDQASSEPQRLIIYMYKDEVRGLA 60
 Db 1 nfgrlhattavirlnndqylfvdkrqpvedmdtdqasasepqrlllymykdevrqla 60
 QY 61 VTLVSKDSKXSTLSCNKKIISFEEMDPENIDIOSDLFFQKRVYGHKKMEFESSLYEG 120
 Db 61 vtlsvkdsksmstlscnkkisfeemdpennididqsdllffqkrvpgnhkmetesslyeg 120
 QY 121 HFLACQKEDDAFKLLIKKKDENGDKSVMTLTNLHQS 157
 Db 121 hflacqkeddafklllkkkdengdksvmtltlnlbg 157
 RESULT 15
 W77091 standard; Peptide: 157 AA.
 AC W77091;
 XX
 DT 16-NOV-1998 (first entry)
 XX

DE Mouse interleukin 18 derivative 2.

XX Mouse; interleukin-18; IL-18; osteoclast; hypercalcaemia; osteopenia;
 KW osteoclastoma Behcet's syndrome; osteosarcoma; arthropathy; osteoporosis;
 RW chronic rheumatoid arthritis; deformity ostitis; primary hyperthyroidism.
 XX

Mus sp.

EP861663-A2.

02-SEP-1998.

24-FEB-1998; 98EP-0301352.

25-FEB-1997; 97JP-0055468.

(HAYB) HAYASHIBARA SEIBUTSU KAGAKU.

Gillespie MT, Horwood NJ, Kurimoto M, Udagawa N;

WPI; 1998-448964/39.

Use of interleukin-18 to inhibit osteoclast formation - in treatment
 of e.g. hypercalcaemia, osteoclastoma, Behcet's syndrome,
 osteosarcoma, chronic rheumatoid arthritis, deformity ostitis,
 primary hyperthyroidism and osteoporosis

Disclousure: Page 34-35; 56pp; English.

Interleukin-18 (IL-18) or a functional equivalent can be used for
 inhibition of osteoclast formation. IL-18 is used for treating or
 preventing osteoclast-related diseases e.g. hypercalcaemia, osteoclastoma
 Behcet's syndrome, osteosarcoma, arthropathy, chronic rheumatoid
 arthritis, deformity ostitis, primary hyperthyroidism, osteopenia and
 osteoporosis.

SQ Sequence 157 AA.

Query Match

Best Local Similarity 98.5%; Score 796; DB 19; Length 157;
 Matches 155; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 NGRRLHCTAVIRININDOVLPEVDRKQPFEDMTDIDQASAPQRLIITYMKDEVRGLA 60
 Db 1 nfgrlhctavirindqylfvdkrpvedmdtdidqsasepqrlllymkdsevrqla 60
 QY 61 VTLGVKDSKXSTLSCNKKIISPEMDPPENIDIDQSLIFQKRVPGHNMKEFESSLYEG 120
 Db 61 vtlsvkdsksxtlscnknkisiPEMDPPENIDIDQSLIFQKRVPGHNMKEFESSLYEG 120
 QY 121 HPLACOKEDDAFLIKKKKDKSGVMTLTLNLAHQ 157
 Db 121 hplacokeddaflilkkkkdsgksvmtltnlhgs 157

Search completed: November 20, 2000, 14:05:59
 Job time: 112 sec

7
.
.
.

1 1 1 1 1 1 1 1 1 1

2

3

4